
    
      This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to
      evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib
      for patients with progressive multiple myeloma.

      The study will consist of a screening period, followed by a treatment period of up to eight
      28-day treatment cycles, followed by a period of maintenance treatment. Subjects are to be
      treated until disease progression.
    
  